The digital therapeutics market is witnessing considerable growth globally thanks to the confluence of the development of new technologies, the increasing prevalence of chronic diseases and lifestyle-associated diseases and an aging population. Exactly how the technology will impact the health care milieu was the subject of a panel held at the Biotechnology Innovation Organization's 2019 international convention earlier this month, organized by Accel-Rx, Canada's health sciences accelerator that supports promising early stage companies developing therapeutics, diagnostics and medical devices.
The digital therapeutics market is witnessing considerable growth globally thanks to the confluence of the development of new technologies, the increasing prevalence of chronic diseases and lifestyle-associated diseases and an aging population.
The digital therapeutics market is witnessing considerable growth globally thanks to the confluence of the development of new technologies, the increasing prevalence of chronic diseases and lifestyle-associated diseases and an aging population.
Biopharmaceutical equities were dragged down in May in lockstep with the general markets, with investors heading for the sidelines due to economic concerns over contentious trade issues and the prospect of tariff wars. As a result, the BioWorld Biopharmaceutical index dropped 5% in the month and is now trading down 6.4% for the year, the same year-to-date performance so far recorded by the Dow Jones Industrial Average.
PHILADELPHIA – Along with the opportunity to hear about the latest science and business developments taking place, delegates attending the BIO 2019 meeting were provided with an update on the state-of-the industry in the U.S. During the event several reports were released that clearly demonstrate biotechnology has become a major economic driver not only for the country, but individual states as well, particularly those that have actively engaged in building and supporting a bioscience infrastructure.
The American Society of Clinical Oncology (ASCO) annual meeting, which closed last week, had fewer standout presentations than in previous years but the many hundreds of studies that were described did serve to demonstrate the sheer volume of clinical cancer research that is currently underway.
PHILADELPHIA – Along with the opportunity to hear about the latest science and business developments taking place, delegates attending the BIO 2019 meeting were provided with an update on the state-of-the industry in the U.S. During the event several reports were released that clearly demonstrate biotechnology has become a major economic driver not only for the country, but individual states as well, particularly those that have actively engaged in building and supporting a bioscience infrastructure.
The American Society of Clinical Oncology (ASCO) annual meeting, which closed last week, had fewer standout presentations than in previous years but the many hundreds of studies that were described did serve to demonstrate the sheer volume of clinical cancer research that is currently underway.
Philadelphia has not been traditionally known as a leading hub for biotechnology innovation and commercialization, in contrast to those hubs located Boston and San Francisco. However, the city is hoping that the more than 16,000 delegates attending the BIO 2019 International Convention this week will learn just how much research and development is taking place and that global recognition for its foundational research in gene and cell therapy has earned it the name of “Cellicon Valley.”
Philadelphia has not been traditionally known as a leading hub for biotechnology innovation and commercialization, in contrast to those hubs located Boston and San Francisco. However, the city is hoping that the more than 16,000 delegates attending the BIO 2019 International Convention this week will learn just how much research and development is taking place and that global recognition for its foundational research in gene and cell therapy has earned it the name of "Cellicon Valley."
